Protective antibodies and T cell responses to Omicron variant after the booster dose of BNT162b2 vaccine

The high number of mutations in the Omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes its immune escape. We report a longitudinal analysis of 111 vaccinated individuals for their antibody levels up to 6 months after the third dose of the BNT162b2 vaccine. After the third dose, the antibody levels decline but less than after the second dose. The booster dose remarkably increases the serum ability to block wild-type or Omicron variant spike protein's receptor-binding domain (RBD) inter-action with the angiotensin-converting enzyme 2 (ACE2) receptor, and these protective antibodies persist 3 months later. Three months after the booster dose, memory CD4(+) and CD8(+) T cells to the wild-type and Omicron variant are detectable in the majority of vaccinated individuals. Our data show that the third dose restores the high levels of blocking antibodies and enhances T cell responses to Omicron.

Automated summary

This study conducted a longitudinal analysis on 111 vaccinated individuals and found that the third dose of the BNT162b2 vaccine restores high levels of blocking antibodies and enhances T cell responses to the Omicron variant.